
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson's strong financial performance in FQ3'25, with Medical Surgical Systems (MMS) sales reaching $888 million, reflects a year-over-year growth of 5.3%, driven by robust demand for Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business has shown consistent annual growth exceeding 6% since the launch of the BD 2025 initiative, alongside improving margins, indicating a positive trend in operational efficiency. Furthermore, the Molecular Diagnostics Solutions (MDS) segment achieved FY24 sales of $4.43 billion, representing a 3.2% increase year-over-year, underscoring the company's diversified revenue streams and resilience in the healthcare market.
Bears say
Becton Dickinson's sales in FQ3'25 showed a decline of 1.1% year-over-year, indicating challenges in key sectors, particularly within Biosciences and Diagnostic Solutions. The company's organic revenue growth outlook has been lowered multiple times, now reflecting a range of 3.0-3.5%, which is significantly reduced from earlier projections. Additionally, headwinds such as volume-based procurement pressures in China and reduced demand due to government research funding cuts contribute to the negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares